<?xml version="1.0" encoding="UTF-8"?>
<boxed-text position="float" orientation="portrait">
 <caption>
  <title>Strengths and limitations of this study</title>
 </caption>
 <p>
  <list list-type="bullet">
   <list-item>
    <p>This is the most up to date and complete study that considers trends in clinical development timelines for new drugs introduced into the UK.</p>
   </list-item>
   <list-item>
    <p>The study used data from the European Medicines Agency, Medicines and Healthcare Products Regulatory Agency and British National Formulary to ensure that all relevant drugs were identified and regulatory dates were accurate.</p>
   </list-item>
   <list-item>
    <p>However, this study considered only the clinical phase of development, from the initiation of clinical trials to regulatory approval and omits the time and resources needed for discovery and preclinical development, as well as postauthorisation activities.</p>
   </list-item>
   <list-item>
    <p>This study did not consider new indications or the repurposing of existing licensed and marketed drugs.</p>
   </list-item>
  </list>
 </p>
</boxed-text>
